About Absolute Clinical Research
Clinical Trials at Absolute Clinical Research
During the past decade, Absolute Clinical Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Absolute Clinical Research
According to Clinical.Site data, the most researched conditions in "Absolute Clinical Research" are
"Covid19" (1 trials) and "Efficacy and Safety" (1 trials). Many other conditions were trialed in "Absolute Clinical Research" in a lesser frequency.
Clinical Trials Intervention Types at Absolute Clinical Research
Most popular intervention types in "Absolute Clinical Research" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (2 trials), "Favipiravir" (1 trials) and "Proxalutamide (GT0918)" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Absolute Clinical Research
The vast majority of trials in "Absolute Clinical Research" are
2 trials for "All" genders.
Clinical Trials Status at Absolute Clinical Research
Currently, there are NaN active trials in "Absolute Clinical Research".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Absolute Clinical Research,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Absolute Clinical Research, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".